The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
April 23rd 2024
The FDA granted accelerated approval to talquetamab on August 9, 2023, as a treatment option for adult patients with relapsed/refractory multiple myeloma (RRMM) who have failed at least 4 prior lines of therapy.
Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care
1.0 Credits / Hematologic Cancer, Oncology
View More
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
1.5 Credits / Oncology, Hematology, Hematologic Cancer
View More
Topline KarMMa-3 Results for Ide-Cel in Multiple Myleoma Show “Significant Improvement” in PFS
August 10th 2022Ide-cel is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, which uses the process of genetically modifying a patient’s T cells and infusing them back into the patient to attack the cancer.
Read More
NGF-Based MRD Assessment Demonstrates Potential to Predict MM Disease Progression
August 4th 2022Previous studies have produced heterogeneous results on next-generation flow (NGF)-based minimal residual disease (MRD) detection, despite improvements to the method’s reproducibility and sensitivity, prompting the present authors to investigate its clinical utility.
Read More
Early Use of Novel Therapies in Multiple Myeloma Could Target Bone Marrow Microenvironment
July 28th 2022Authors explained how multiple myeloma emerges from earlier clinical phases and the tumor’s microenvironment in the early course of the disease plays a critical role in the survival of myeloma cells.
Read More
Survey Finds Shift in Clinician Views of MRD Status in Treatment Decisions for Multiple Myeloma
July 16th 2022Results looking at acceptance of minimal residual disease (MRD) status found that 60% of participants “would change at least one decision based on an MRD result,” and 54% would use both MRD status and disease risk to make decisions.
Read More
Interim Phase 2 Trial Results Show Quadruplet Regimen Tolerable, Effective in MM
June 25th 2022Early results of a multicenter phase 2 trial exploring the efficacy of daratumumab, pomalidomide, dexamethasone, and ixazomib treatment suggest the regimen is safe and effective in relapsed or refractory multiple myeloma (MM).
Read More
Standard-of-Care Treatments Insufficient in Improving QOL for Patients With Multiple Myeloma
June 19th 2022Patients with multiple myeloma frequently relapse and experience deteriorating quality of life, according to findings from the LocoMMotion study, which also reported that specific patient and disease characteristics are associated with poor efficacy outcomes.
Read More
Vitamin D Provides Therapeutic Benefit Among Patients With MM, Review Says
June 15th 2022A literature review revealed that supplementation with vitamin D could provide therapeutic benefits for patients with multiple myeloma (MM) who are undergoing chemotherapy. However, more research is needed to confirm findings.
Read More
High Economic Burden of MM, Particularly Within 1 Year of Diagnosis, Says French Study
June 4th 2022As more treatments continue to enter the market for multiple myeloma (MM), the cost of associated treatments is expected to continue climbing, with the researchers of the study emphasizing the need for more effective and options to help mitigate costs.
Read More
Low Socioeconomic Status May Account for Ethnic Survival Disparities in MM
June 3rd 2022The researchers found that socioeconomic status likely drives survival disparities between Hispanic patients and non-Hispanic whites (NHWs). They also found that, while both underserved populations, Hispanics and non-Hispanic blacks have different survival outcomes compared with NHWs.
Read More
Serum IgG Subclass May Be Indicator of Treatment Effect in Multiple Myeloma
May 18th 2022The researchers found that among subclasses, IgG1 expression was most prominent in samples from patients with multiple myeloma, and expression of IgG1 changed significantly before, throughout, and following treatment.
Read More
Repurposing a Drug Used for Alcohol Abuse May Overcome MM Treatment Resistance
May 15th 2022According to recent findings, metabolizing disulfiram into diethyldithiocarbamate-copper complex creates a proteasome inhibitor-like treatment that enables the efficient killing of treatment-resistant multiple myeloma (MM) cells.
Read More